Updates and Research Trends in Peripheral T-Cell Lymphoma From ASH 2025

Francine Foss, MD, and Matthew Lunning, DO, FACP, detail current treatment approaches for peripheral T-cell lymphoma.

Francine Foss, MD, and Matthew Lunning, DO, FACP, discuss varying treatment approaches for peripheral T-cell lymphoma in newly diagnosed vs relapsed disease.

Francine Foss, MD, and Matthew Lunning, DO, FACP, highlight key findings from the PRIMO trial evaluating duvelisib in relapsed/refractory peripheral T-cell lymphoma.

Francine Foss, MD, and Matthew Lunning, DO, FACP, look ahead to the phase 3 TERZO trial of duvelisib in nodal TFH peripheral T-cell lymphoma.

Francine Foss, MD, and Matthew Lunning, DO, FACP, discuss findings for duvelisib plus chidamide and CHOP in newly diagnosed angioimmunoblastic T-cell lymphoma.

Francine Foss, MD, and Matthew Lunning, DO, FACP, discuss other key data from ASH 2025 and ongoing research to watch in peripheral T-cell lymphoma.